首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
【24h】

D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.

机译:与氟哌啶醇不同,D2多巴胺反义RNA表达载体可长期抑制D2多巴胺介导的行为,而不会引起D2多巴胺受体的上调。

获取原文
获取原文并翻译 | 示例
       

摘要

Long-term inhibition of D2 dopamine receptors using classic D2 dopamine receptor antagonists such as haloperidol often causes a compensatory up-regulation of the D2 dopamine receptors. We investigated whether the long-term inhibition of D2 dopamine receptors using an eukaryotic expression vector housing a cDNA sequence encoding an antisense RNA directed to the D2 dopamine receptor transcript (D2 antisense vector) would also produce up-regulation of the D2 receptors. Single, bilateral injections of the D2 antisense vector into the corpora striata of mice inhibited the stereotypy induced by acute challenge injections with the D2/D3 dopamine receptor agonist quinpirole but did not inhibit the grooming induced by acute challenge injections with the D1 agonist SKF 38393. Similar treatment with the D2 antisense vector produced a long-term (>1 month) cataleptic response without producing tolerance to challenge injections with haloperidol. By contrast, catalepsy induced by a single injection of haloperidol lasted only approximately 2 days, and tolerance developed to its effects after long-term treatment. Repeated treatment of mice with haloperidol resulted in an inhibition of apomorphine-induced climbing behavior throughout the time of treatment with haloperidol, but the climbing behavior markedly increased to levels significantly higher than that of the control mice immediately after withdrawal from haloperidol treatment. This increased climbing was accompanied by increased levels of D2 dopamine receptors in the striatum. By contrast, single, bilateral intrastriatal injections of the D2 antisense vector significantly inhibited apomorphine-induced climbing for approximately 30 days but failed to increase the climbing behavior or the levels of D2 dopamine receptors in striatum over those of the control values. These results suggest that a single injection of a D2 antisense RNA expression vector into mouse striatum produces specific, long-term inhibition of D2 dopamine receptor behaviors without causing a compensatory increase in the levels or function of D2 dopamine receptors.
机译:使用经典的D2多巴胺受体拮抗剂(如氟哌啶醇)长期抑制D2多巴胺受体通常会引起D2多巴胺受体的补偿性上调。我们调查了使用真核表达载体对D2多巴胺受体的长期抑制作用,该载体含有编码针对D2多巴胺受体转录物的反义RNA的cDNA序列(D2反义载体)是否也会产生D2受体的上调。将D2反义载体单次,双边注射到小鼠的体状体中,可以抑制D2 / D3多巴胺受体激动剂喹吡罗急性发作注射引起的刻板印象,但不能抑制D1激动剂SKF 38393急性发作注射诱导的修饰。用D2反义载体进行的类似治疗产生了长期(> 1个月)的抗感性反应,而对氟哌啶醇的注射挑战没有耐受性。相比之下,单次注射氟哌啶醇引起的僵直症仅持续约2天,经过长期治疗后其耐受性逐渐增强。在氟哌啶醇治疗的整个过程中,用氟哌啶醇重复治疗小鼠均会抑制阿扑吗啡诱导的爬升行为,但从氟哌啶醇治疗撤出后,其爬升行为显着增加至明显高于对照小鼠的水平。这种增加的攀爬伴随着纹状体中D2多巴胺受体水平的增加。相比之下,D2反义载体的单次,双侧纹状体内注射显着抑制了阿扑吗啡诱导的爬升约30天,但未能增加爬升行为或纹状体中D2多巴胺受体的水平超过对照值。这些结果表明,向小鼠纹状体单次注射D2反义RNA表达载体可产生D2多巴胺受体行为的特异性长期抑制,而不会引起D2多巴胺受体水平或功能的补偿性增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号